Neurological manifestations of coinfection with HIV and HTLV-1

dc.creatorSilva, Marcus T. T.
dc.creatorNeves, Elizabeth S.
dc.creatorGrinsztejn, Beatriz
dc.creatorEspíndola, Otávio de Melo
dc.creatorSchor, Doris
dc.creatorAraújo, Abelardo
dc.date2019-10-11T11:59:15Z
dc.date2019-10-11T11:59:15Z
dc.date2012
dc.date.accessioned2023-09-26T20:21:12Z
dc.date.available2023-09-26T20:21:12Z
dc.identifierSILVA, Marcus T. T. et al. Neurological manifestations of coinfection with HIV and human T-lymphotropic virus type 1. AIDS, v. 26, n. 4, p. 521-523, 2012.
dc.identifier0269-9370
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/36375
dc.identifier10.1097/QAD.0b013e32835049be
dc.identifier1473-5571
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8854931
dc.descriptionHIV-individuals are at risk for human T-lymphotropic virus (HTLV) coinfection and neurological diseases. Little is known about the impact of HAART among coinfected patients. In this study, 47 out of 428 HIV individuals were coinfected with HTLV (10.9%). Coinfection was an independent variable associated with neurological outcome (odds ratio 8.73). Coinfection was associated with myelopathy [chi square (X2 ) U 93, P< 0.001], peripheral neuropathy (X2 U 6.5, P U 0.01), and hepatitis C virus infection (X2 U 36.5, P< 0.001). HAART did not appear to protect against neurological diseases and had no impact on HTLV proviral load.
dc.description2020-10-11
dc.formatapplication/pdf
dc.languageeng
dc.publisherLippincott, Williams & Wilkins
dc.rightsopen access
dc.subjectHIV
dc.subjectHTLV-1
dc.subjectNeurological manifestations
dc.subjectCoinfection
dc.titleNeurological manifestations of coinfection with HIV and HTLV-1
dc.typeArticle


Este ítem pertenece a la siguiente institución